Hints and tips:
...Sell: Oxford BioMedica (OXB) Considering Oxford BioMedica is due to earn royalties on the sales of cancer drug Kymriah, it is unsurprising shares responded well to its approval....
...My best performers included two firms in the pharmaceuticals sector: BTG, whose shares were up from 231.4p to 293.7p; and Oxford BioMedica, up 5.53p to 7.05p....
...I have shareholdings in the multinational Novartis and a number of minnows, such as BTG, Immupharma and Oxford Biomedica. Oxford announced its preliminary results for 2009 on March 10....
...At the close on Friday, Oxford BioMedica had a market capitalisation of £46.5m. Both GeneThera and Oxford BioMedica were unavailable for comment....
...Oxford BioMedica, a well-known UK biotech company which spun out of Oxford University, has been based there since 1997....
...Hopefully, this means my Sipp’s holdings in such companies as ImmuPharma, Oxford BioMedica and Protherics will benefit from increased joint venture activity and more financial backing from major firms....
...Biotechnology group Oxford Biomedica rose 2.3 per cent to 32¾p, buoyed by news of a breakthrough in its work to produce the human protein interferon beta-la....
...Among the smaller companies, Oxford Biomedica dropped 8.3 per cent to 27½p after the gene therapy group announced it has met with institutional investors with a view to raising £20m to £30m through a placing...
...Oxford Biomedica rose 2.2 per cent to 35p amid speculation the gene therapy group was close to agreeing a deal with Pfizer to develop TroVax, a colon cancer treatment....
...Oxford BioMedica firmed 0.9 per cent at 27p amid hopes that Trovax, its cancer treatment, could prove a major money-spinner for the biotechnology group....
...Oxford Biomedica gained another 11.3 per cent to 27p on continued bid speculation. An acquistion and trading update helped Interregnum, the technology merchant bank, rise 13.7 per cent to 7.25p....
...After a rise of 11.6 per cent on Tuesday, Oxford Biomedica jumped 18.2 per cent to 22.75p on news that the biotechnology company is in merger discussions with an unnamed company....
International Edition